Viewing nowMegapregablin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
L&C Bio Co., Ltd.

MFDS item code 202001372 · Approved 2020.02.27 · Insurance code 060500380
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication effectively treats peripheral and central neuropathic pain in adults. It is also used as an adjunctive therapy for partial seizures in patients with epilepsy, helping to control seizures. It contributes to the alleviation of symptoms in patients with fibromyalgia. It is widely used for various neurological disorders, improving patients' quality of life.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, regardless of food. The dose should be adjusted in patients with impaired renal function. Peripheral neuropathic pain Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. Central neuropathic pain Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. Fibromyalgia The recommended dose is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. Discontinuation of treatment If treatment is discontinued, it should be tapered gradually over at least 1 week. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children younger than 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if any mood changes or abnormal behavior signs occur during treatment, it should be reported to a healthcare professional immediately. Patients with allergies to the ingredients in this medication or those who have issues digesting lactose should not take this drug. Diabetic patients should be cautious as weight gain may require adjustments to diabetes medication doses. If symptoms of angioedema occur, the use of this medication should be discontinued immediately and consultation with a healthcare professional should be sought. Elderly patients are at higher risk of falling or injury due to dizziness or drowsiness caused by this medication. Vision changes, such as blurred vision, may occur, and if such symptoms appear, consultation with a healthcare professional is recommended. Abruptly discontinuing the medication may lead to withdrawal symptoms like insomnia, headaches, and anxiety, so it should be tapered off gradually following a healthcare professional's guidance. There is a risk of drug abuse or dependency, so patients with a history of substance abuse should be particularly cautious. Patients with severe cardiovascular disease or impaired kidney function may require dose adjustments, and caution is advised when taken with opioid analgesics due to an increased risk of central nervous system depression. Pregnant women should avoid this medication during the early stages of pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. This medication may cause dizziness and drowsiness, so caution is necessary when driving or operating dangerous machinery. Severe skin reactions may occur rarely; if abnormal skin symptoms develop, the medication should be stopped immediately and the healthcare professional informed. In case of overdose, signs such as confusion, drowsiness, or seizures may occur, requiring immediate medical attention. Keep out of reach of children and avoid transferring to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is advisable to keep the storage temperature between 15 to 30 degrees Celsius.
A hard capsule with a white or light yellow powder inside that appears white.
30 capsules per bottle, 60 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
L&C Bio Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.